Some of the clinical trials that we are currently participating in are:
Sponsor: Selexys Pharmaceuticals Corporation
This randomized, placebo-controlled, double-blind study is being conducted to determine the efficacy and safety of SelG1 when administered once every 4 weeks for 52 weeks to patients with a diagnosis of sickle cell disease who may or may not be receiving hydroxyurea and have experienced between 2 and 10 pain crisis in the 12 months preceding enrollment in this study.
Rivipansel is a glycomimetic inhibitor of E-, P-, and L-selectins in vitro. Rivipansel has been shown to inhibit inflammation in several animal models of disease, including the mouse model of vaso-occlusive crisis (VOC) of sickle cell disease (SCD). It has also been shown to consistently improve multiple clinically meaningful measures of the VOC experience, for both the pediatric and adult subjects enrolled in the Phase 2 study (GMI-1070-201). This Phase 3 study will continue to examine rivipansel for the treatment of VOC in patients with SCD.
Investigator-Initiated, under Dr. Stacy Drury
This proposal seeks to examine the neurocognitive findings in children and adults with sickle cell disease, and sickle cell trait carriers with and without evidence of changes on MRI or abnormal Doppler CNS vascular flow.
Investigator-Initiated, under Dr. Tammuella Singleton
This study examines whether or not, exchange and simple transfusions will decrease blood velocity in patients with sickle cell disease. The hope is that this may be the basis of future studies to determine whether TCD is an acceptable tool to measure middle cerebral artery flow as a surrogate of stroke risk. This surrogate might be useful to determine the length of interval between exchange and simple transfusions in this patient population.
Sponsor: Doris Duke Charitable Foundation (DDCF)
A multicenter controlled study to compare the prevalence of patent foramen ovale (PFO) or other potential intracardiac shunts detectible by transthoracic echocardiography (TTE) by conventional 2-D, color Doppler, and agitated saline-contrast studies in children with sickle cell disease and stroke to a control group of patients without sickle cell disease or stroke.